TOP 1901 (Non-Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how an experimental combination of drugs (atezolizumab + bevacizumab) works in your body and against your cancer.

What is the Condition Being Studied?

Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults age 18 or older who:
- Are diagnosed with EGFR mutant NSCLC
- Had their cancer get worse while receiving osimertinib

For more information about who can be in this study, please contact the study team.

Age Group
Adults

What is Involved?

This study is divided into 2 parts: a screening period and a study dosing period.

If you join this study, during the screening period you will:
- Have blood draws
- Visit the clinic for various tests to see if you’re eligible for the dosing period

If you're eligible for the dosing period, you will:
- Receive the study drugs atezolizumab and bevacizumab
- Come to the clinic clinic every 3 weeks to receive the study drugs
- Have blood draws
- Have imaging scans (CT and MRI)

Study Details

Full Title
Single arm phase 2 trial of atezolizumab and bevacizumab in Epidermal Growth Factor Receptor (EGFR) mutant non?small cell lung cancer in patients with progressive disease after receiving osimertinib (TOP 1901)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00103723
NCT: NCT04099836
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698